Alembic Pharmaceuticals is trading at RS. 959.60, up by 13.80 points or 1.46% from its previous close of RS. 945.80 on the BSE.

The stock opened at RS. 958.80 and has touched a high of RS. 971.90 and a low of RS. 948.00 so far, with 3689 shares changing hands.

Classified in the BSE group 'A' with a face value of RS. 2, the scrip has recorded a 52-week high of RS. 1296.15 on October 9, 2024, and a 52-week low of RS. 725.60 on March 3, 2025. Over the past week, it traded between a high of RS. 971.90 and a low of RS. 927.80. The company’s current market capitalization stands at RS. 18870.06 crore.

Promoters hold 69.67% of the shares, while institutions and non-institutions own 20.42% and 9.90% respectively.

Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its API-I and API-II facilities in Panelav between May 26, 2025, and May 31, 2025.

Founded in 1907, Alembic Pharmaceuticals is a vertically integrated pharmaceutical company with a strong focus on research and development, delivering healthcare solutions globally.